P. Leia Nghiemphu, MD

Phioanh (Leia) NghiemPhu, MD

Associate Professor of Clinical Neurology, Department of Neurology, Neurological Services, Neuro-Oncology Program, Brain Tumor Program
Director of Clinical Service, Department of Neurology, Neuro-Oncology Program
Director of Operations, Brain Tumor Center
Director, UCLA NF2 Clinic


English, Vietnamese



Institutional Affiliation

Ronald Reagan UCLA Medical Center



Neuro-Oncology, UCLA Neuro-Oncology Program, 2003-2006


Medicine, Beth Israel Medical Center, New York, NY 1999-2000


MD, Albert Einstein College of Medicine, 1999


Neurology, Stanford Medical Center, 2000-2003

Board Certification

Neurology, Neuro-Oncology, American Board of Psychiatry and Neurology, 2004, 2014

Contact Information

Clinical Interests

Brain Tumors, Neuro-Oncology

Scientific Interests

Dr. Leia NghiemPhu's research interest focuses on finding individualized molecular therapy for patients with malignant brain cancer. Her main goal lies in designing molecularly driven clinical trials that can provide tissues to understand mechanisms of response and resistance to molecular therapies for brain cancer. Her works to date mainly concentrate on aberrant pathways in glioblastoma and anti-angiogenic treatments.

Highlighted Publications

Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009 Apr 7;72(14):1217-22.

Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008 Oct;249(1):268-77.

Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008 Jun;10(3):355-60. Epub 2008 Apr 24.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22;5(1):e8.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. Epub 2007 Dec 6.